Literature DB >> 1324063

Imidazoline binding sites in human placenta: evidence for heterogeneity and a search for physiological function.

S Diamant1, T Eldar-Geva, D Atlas.   

Abstract

1. An alpha 2-adrenoceptor antagonist, idazoxan, that binds to both alpha 2-adrenoceptors and to imidazoline sites (IR), has been used to characterize human placental IR. Human placenta is shown to be the richest source of IR (1800 +/- 100 fmol mg-1 protein; Kd 38.9 +/- 3.4 nM). 2. Primary cells derived from human placenta and grown in monolayers, also displayed a high density of receptors (3209 +/- 136 fmol mg-1 in cytotrophoblasts and 3642 +/- 144 fmol mg-1 protein in syncytiotrophoblast enriched cell culture). 3. [3H]-idazoxan did not show binding characteristics of alpha 2-adrenoceptors in human placental membranes or human trophoblastic cells, thus making it a ligand of choice to study the imidazoline site. The tissue appeared to be lacking alpha 2-adrenoceptors in that other alpha 2-adrenoceptor ligands, [3H]-rauwolscine and [3H]-clonidine, do not bind to alpha 2-adrenoceptors in human placenta. 4. IRs are localized on the cell surface, as determined by the release of bound [3H]-idazoxan from cells, when washed with high ionic/acidic medium. 5. Imidazoline receptors of human placenta display high affinity for amiloride (72 +/- 27 nM). The high affinity was used as a criterion to classify IR to IRa subtype (placenta, rabbit kidney, rabbit liver and rabbit adipose cells) as opposed to the IRb subtype which display low affinity for amiloride (greater than 2 microM, in all the other tissues).6. Several novel ligands comprising a guanido functional group attached to an aromatic residue (e.g. benziliden-amino-guanidine (BAG), guanido pyrole) display pronounced selectivity for IR over the M2-adrenoceptors as the affinity of BAG is about 40 fold higher (Kd= 18.9 +/- 13.8 nM in human placenta), than the affinity for M2-adrenoceptors (Kd = 768 +/- 299 nM in human platelets). Imidazoline sites bind selectively BAG and other guanido ligands thus indicating a distinct structural requirement at its site of binding.7. K+ channel blockers and monovalent ions (e.g. Cs' and NH4+) interfere with idazoxan binding to IR, indicating a possible involvement of IR in K+ transport.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1324063      PMCID: PMC1907438          DOI: 10.1111/j.1476-5381.1992.tb14300.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  38 in total

Review 1.  Clonidine-displacing substance (CDS) and its putative imidazoline receptor. New leads for further divergence of alpha 2-adrenergic receptor activity.

Authors:  D Atlas
Journal:  Biochem Pharmacol       Date:  1991-06-01       Impact factor: 5.858

2.  Characterization of chloride channels in membrane vesicles from the kidney outer medulla.

Authors:  W Breuer
Journal:  J Membr Biol       Date:  1989-01       Impact factor: 1.843

Review 3.  Ion transport by the placenta: a review of membrane transport systems.

Authors:  D B Shennan; C A Boyd
Journal:  Biochim Biophys Acta       Date:  1987-10-05

4.  Inhibition of chemotactic factor-activated Na+/H+ exchange in human neutrophils by analogues of amiloride: structure-activity relationships in the amiloride series.

Authors:  L Simchowitz; E J Cragoe
Journal:  Mol Pharmacol       Date:  1986-08       Impact factor: 4.436

5.  Imidazoline-guanidinium receptive site in renal proximal tubule: asymmetric distribution, regulation by cations and interaction with an endogenous clonidine displacing substance.

Authors:  I Coupry; D Atlas; R A Podevin; I Uzielli; A Parini
Journal:  J Pharmacol Exp Ther       Date:  1990-01       Impact factor: 4.030

6.  [3H]idazoxan and some other alpha 2-adrenergic drugs also bind with high affinity to a nonadrenergic site.

Authors:  M C Michel; O E Brodde; B Schnepel; J Behrendt; R Tschada; H J Motulsky; P A Insel
Journal:  Mol Pharmacol       Date:  1989-03       Impact factor: 4.436

7.  Neutral amino acid transport systems of microvillous membrane of human placenta.

Authors:  L W Johnson; C H Smith
Journal:  Am J Physiol       Date:  1988-06

8.  Effect of imidazolines on Na+ transport and intracellular pH in renal proximal tubule cells.

Authors:  M Bidet; P Poujeol; A Parini
Journal:  Biochim Biophys Acta       Date:  1990-05-09

9.  Imidazoline receptors in rat liver cells: a novel receptor or a subtype of alpha 2-adrenoceptors?

Authors:  R Zonnenchein; S Diamant; D Atlas
Journal:  Eur J Pharmacol       Date:  1990-11-06       Impact factor: 4.432

10.  Guanabenz, guanochlor, guanoxan and idazoxan bind with high affinity to non-adrenergic sites in pig kidney membranes.

Authors:  P Vigne; M Lazdunski; C Frelin
Journal:  Eur J Pharmacol       Date:  1989-01-31       Impact factor: 4.432

View more
  14 in total

1.  CR4056, a powerful analgesic imidazoline-2 receptor ligand, inhibits the inflammation-induced PKCε phosphorylation and membrane translocation in sensory neurons.

Authors:  Vittorio Vellani; Chiara Sabatini; Chiara Milia; Gianfranco Caselli; Marco Lanza; Ornella Letari; Lucio Claudio Rovati; Chiara Giacomoni
Journal:  Br J Pharmacol       Date:  2019-11-07       Impact factor: 8.739

2.  Non-adrenergic binding of [3H]atipamezole in rat kidney--regional distribution and comparison to alpha2-adrenoceptors.

Authors:  B Sjöholm; J Lähdesmäki; K Pyykkö; M Hillilä; M Scheinin
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

Review 3.  Imidazoline I2 receptors: An update.

Authors:  Jun-Xu Li
Journal:  Pharmacol Ther       Date:  2017-03-16       Impact factor: 12.310

4.  Pharmacological modulation of immunoreactive imidazoline receptor proteins in rat brain: relationship with non-adrenoceptor [3H]-idazoxan binding sites.

Authors:  P V Escribá; R Alemany; M Sastre; G Olmos; A Ozaita; J A García-Sevilla
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

5.  The anti-emetic effects of CP-99,994 in the ferret and the dog: role of the NK1 receptor.

Authors:  J W Watson; S F Gonsalves; A A Fossa; S McLean; T Seeger; S Obach; P L Andrews
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

6.  [3H]-idazoxan binding to rabbit cerebral cortex recognises multiple imidazoline I2-type receptors: pharmacological characterization and relationship to monoamine oxidase.

Authors:  A Renouard; P S Widdowson; A Cordi
Journal:  Br J Pharmacol       Date:  1993-07       Impact factor: 8.739

7.  Relevance of the use of [3H]-clonidine to identify imidazoline receptors in the rabbit brainstem.

Authors:  G Bricca; J Zhang; H Greney; M Dontenwill; J Stutzmann; A Belcourt; P Bousquet
Journal:  Br J Pharmacol       Date:  1993-12       Impact factor: 8.739

8.  Chronic treatment with the monoamine oxidase inhibitors clorgyline and pargyline down-regulates non-adrenoceptor [3H]-idazoxan binding sites in the rat brain.

Authors:  G Olmos; A M Gabilondo; A Miralles; P V Escriba; J A García-Sevilla
Journal:  Br J Pharmacol       Date:  1993-03       Impact factor: 8.739

9.  [3H]idazoxan binding to bovine adrenal medullary membranes: identification and pharmacological characterization of I2-imidazoline sites.

Authors:  G J Molderings; L Kundt; M Göthert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-09       Impact factor: 3.000

10.  Changes of imidazoline receptors in spontaneously hypertensive rats.

Authors:  Guang-Yuan Mar; Ming-Ting Chou; Hsien-Hui Chung; Nien-Hua Chiu; Mei-Fen Chen; Juei-Tang Cheng
Journal:  Int J Exp Pathol       Date:  2012-11-24       Impact factor: 1.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.